Sipai Health Technology Co (FRA:AX1) Growth Rank: 7 (As of Aug. 20, 2026) — 17% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX1 Sipai Health Technology Co Ltd FRA:AX1
64 GF Score
Price €0.14
GF Value €0.22
! 5 Warning Signs
View Full Analysis

What is Sipai Health Technology Co Growth Rank?

Sipai Health Technology Co FRA:AX1 -2.80% 64 Growth Rank is 7 as of Aug. 20, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates FRA:AX1 with a GF Score™ of 64/100 and a GF Value™ of €0.22. The stock has 5 warning signs investors should review.

Sipai Health Technology Co has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sipai Health Technology Co Growth Rank Related Terms

FRA:AX1 vs MCK, COR, CAH: Growth Rank Comparison

For the Medical Distribution subindustry, Sipai Health Technology Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sipai Health Technology Co Growth Rank vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sipai Health Technology Co's Growth Rank falls into.


FRA:AX1
64GF Score
Sipai Health Technology Co Ltd FRA:AX1
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Sipai Health Technology Co (FRA:AX1) has a Growth Rank of 7 as of Aug. 20, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sipai Health Technology Co and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Sipai Health Technology Co's Growth Rank has ranged from 2.00 to 9.00.
Is Sipai Health Technology Co's Growth Rank too high?
Sipai Health Technology Co's current Growth Rank of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Sipai Health Technology Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's Growth Rank compare to MCK and COR?
Sipai Health Technology Co's Growth Rank of 7 can be compared against companies in the Medical Distribution industry. Historically, Sipai Health Technology Co's own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Distribution company?
A good Growth Rank depends on the Medical Distribution industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sipai Health Technology Co and its competitors. Sipai Health Technology Co's current Growth Rank is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Sipai Health Technology Co (FRA:AX1) has a current Growth Rank of 7. The stock's GF Value™ is €0.22, compared to a current price of €0.14 — trading 36.8% below its estimated fair value. The current Growth Rank is 7, which is 17% above median its 10-year median of 6.00. Sipai Health Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sipai Health Technology Co (FRA:AX1), the current Growth Rank is 7 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sipai Health Technology Co (FRA:AX1) Overvalued in 2026?

Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued. The current stock price of €0.14 is trading 36.8% below its estimated GF Value™ of €0.22.

Key valuation signals for FRA:AX1:

  • Growth Rank: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: €0.22 vs. price of €0.14 (36.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:AX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sipai Health Technology Co Business Description

Other Exchanges 00314:Hong Kong
Address 128 Tianmu West Road, 1603-1605A, 16th Floor, Tower 1, Kerry Enterprise Center, Jing\'an District, Shanghai, CHN
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
64GF Score

Get the complete analysis for FRA:AX1

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.22
GF Value